CNCE stock hits 52-week high on data for antihypertensive agent (NASDAQ:CNCE)
News of a successful Phase 2 trial for CinCor Pharma’s (CNCE) lead asset baxdrostat sent the company shares ~50% higher on Monday towards a 52-week high as Oppenheimer cheered…
CNCE stock hits 52-week high on data for antihypertensive agent (NASDAQ:CNCE)
News of a successful Phase 2 trial for CinCor Pharma’s (CNCE) lead asset baxdrostat sent the company shares ~50% higher on Monday towards a 52-week high as Oppenheimer cheered…